The Department of Defense has published its updated Section 1260H list of “Chinese military companies” this week, and WuXi AppTec along with 27 other new entities were identified on the list. (Federal Register notice available here: https://public-inspection.federalregister.gov/2026-11571.pdf.) DoD noted that WuXi AppTec is named on the basis of indirect ownership by China’s state
Latest from Life Sciences Perspectives
FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides
On April 15, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it will convene a public meeting of the Pharmacy Compounding Advisory Committee (“PCAC”) on July 23-24, 2026, to consider whether to recommend seven (7) peptide bulk drug substances for inclusion on the list of substances that may be used in compounding under
Navigating the EU Data Act: Key Obligations and a Spotlight on Switching Rights
Regulation (EU) 2023/2854 (the Data Act) entered into force across the EU on 12 September 2025. It forms a key part of the EU’s broader data strategy and establishes a comprehensive framework for how data is accessed, used, and shared across connected products, digital services, and data processing services, including cloud and edge computing services.
Life Sciences and Medtech Policy Update: Key Things to Know Q4 2025
To help companies and investors stay ahead of the rapidly evolving regulatory landscape across pharmaceuticals, biologics, medical devices, diagnostics, and laboratory testing, our Life Sciences Regulatory & Compliance team provides timely insights into key developments. Each quarter, we publish a tracker spotlighting the most impactful regulatory updates—essential intelligence for industry leaders navigating change. You can
Antitrust Life Sciences Quarterly Update 2025 Q2
The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck’s $3.9 billion acquisition of SpringWorks, Sanofi’s $9.5 billion acquisition of Blueprint Medicines, and Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, as well as notable developments in litigation and enforcement by European and UK
Move Fast: FDA is Accepting Submissions for the Pilot Program Class for FDA Commissioner’s National Priority Voucher Program
FDA is now accepting submissions to the Commissioner’s National Priority Voucher (CNPV) pilot program, and with only five vouchers to be awarded as part of the initial year of the program, the competition is anticipated to be fierce. It has been a little over a month since the FDA announced the CNPV pilot program, and
DOJ-HHS Announces False Claims Act Working Group, Emphasizes Healthcare Fraud Enforcement Priorities
The Trump administration recently announced the renewal of a new cross-agency collaboration between the Department of Justice (DOJ) and the Department of Health and Human Services (HHS) in the form of the DOJ-HHS False Claims Act Working Group. The Working Group will be jointly led by Deputy Assistant Attorney General (DAAG) of the Commercial
FDA’s Push for “Radical Transparency”: Key Takeaways from the Agency’s Publication of Complete Response Letters
On July 10, 2025, the U.S. Food and Drug Administration (FDA) announced publication of over 200 complete response letters (CRLs) issued in response to applications submitted to FDA for approval of drugs or biologics between 2020 and 2024. The FDA has described this move as a step toward the Agency’s “broader initiatives to modernize and
A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2025 and Beyond
To help companies and investors navigate the many evolving and emerging laws and regulations across pharmaceuticals, biologics, medical devices, diagnostics, and laboratory testing, our Life Sciences Regulatory & Compliance team has provided an overview of key developments. We update and publish a quarterly tracker detailing these developments. You can read about the Q3 2025 updates
One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry
On July 3, 2025 Congress passed, and on July 4, 2025 President Trump signed into law, the One Big Beautiful Bill Act (OBBB), which extends various expiring tax provisions from the Tax Cuts and Jobs Act and introduces a variety of other substantial tax law changes. The developments highlighted below are expected to have particular